Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 10/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924383 | 1.00 | TLR2 (0.57) | TLR2MEN1THRBHTTKMT2A | |
| SCHEMBL15071438 | 0.95 | TLR2 (0.57) | TLR2LPAR1LPAR3ACHE | |
| SCHEMBL14950501 | 0.91 | TLR2 (0.58) | TLR2LPAR1LPAR3 | |
| SCHEMBL18057125 | 0.90 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL10819300 | 0.90 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL18057124 | 0.90 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL11304197 | 0.90 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL25515284 | 0.90 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL14924767 | 0.89 | TLR2 (0.56) | TLR2LPAR1LPAR3 | |
| SCHEMBL24470621 | 0.88 | TLR2 (0.64) | TLR2LPAR1LPAR3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152516-A1 | METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY | NITTO DENKO CORPORATION (JP) | 2017-06-01 | — | — | US | disclosed |
| US-20170152516-A1 | METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY | NITTO DENKO CORPORATION (JP) | 2017-06-01 | — | — | US | disclosed |
| US-9579338-B2 | Method of producing lipid nanoparticles for drug delivery | NITTO DENKO CORPORATION (JP) | 2017-02-28 | — | — | US | disclosed |
| US-9579338-B2 | Method of producing lipid nanoparticles for drug delivery | NITTO DENKO CORPORATION (JP) | 2017-02-28 | — | — | US | disclosed |
| US-8956572-B2 | Single use system for sterilely producing lipid-nucleic acid particles | NITTO DENKO CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8956572-B2 | Single use system for sterilely producing lipid-nucleic acid particles | NITTO DENKO CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20130115274-A1 | METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY | NITTO DENKO CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130115274-A1 | METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY | NITTO DENKO CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115274-A1 | METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY | PHOSPHO1, LIPA, LIPC | TLR2 4529/4885MEN1 1326/4885THRB 4540/4885 |
| US-20170152516-A1 | METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY | PHOSPHO1, LIPA, LIPC | TLR2 4529/4885MEN1 1326/4885THRB 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.